Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pandorum Technologies is a deep-tech biotechnology company specializing in tissue engineering and regenerative medicine. Founded in 2011, the company leverages proprietary 3D bioprinting technology and advanced biomaterials to develop functional human tissues for therapeutic use. Their flagship product, "Liquid Cornea" (KeraGraft), is a regenerative treatment designed to restore vision in patients with corneal scarring or blindness by promoting natural tissue repair. Additionally, Pandorum is advancing a pipeline of bio-engineered liver tissues and exosome-based therapies targeting chronic lung and liver diseases. The company operates research and development facilities in both India and the United States, aiming to provide off-the-shelf regenerative solutions for global healthcare needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pandick Technologies.